Aerogen Pharma, a developer of innovative inhaled treatments for patients in critical care, and Nuance Pharma (“Nuance”), a specialty care focused biopharma with late‐stage clinical programs and existing commercial operations, today announce an exclusive agreement to join forces in Greater China to develop a superior, non‐invasive approach to treatment of RDS, a life‐threatening condition of preterm infants associated with long‐term lung health issues in survivors.
The licensing agreement grants Nuance the exclusive rights to develop and commercialize AeroFact™, an innovate new therapy combining a well‐established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in Greater China (Mainland China, Taiwan, Hong Kong and Macau).
The partners believe that AeroFact offers the prospect of an efficient, non‐invasive, and easy‐to‐use product with benefits over conventional invasively‐delivered lung surfactant that will improve clinical outcomes for the hundreds of thousands of premature babies around the world whose healthy development is threatened by RDS.
The licensing agreement grants Nuance the exclusive rights to develop and commercialize AeroFact™, an innovate new therapy combining a well‐established pulmonary surfactant drug with proprietary vibrating mesh nebulizer aerosolization technology, in Greater China (Mainland China, Taiwan, Hong Kong and Macau).
The partners believe that AeroFact offers the prospect of an efficient, non‐invasive, and easy‐to‐use product with benefits over conventional invasively‐delivered lung surfactant that will improve clinical outcomes for the hundreds of thousands of premature babies around the world whose healthy development is threatened by RDS.
